CD274 and cancer: Although Koneru et al. indirectly compared the safety and efficacy of PD-1 and PD-L1 antibodies across solid tumors and reported no significant differences [39], a prior meta-analysis with head-to-head comparison nonetheless demonstrated favorable OS outcomes of PD-1 inhibitors in cancer treatment [40].